# From Exposure to Dysfunction: The Intestinal Toxicity of Per- and Polyfluoroalkyl Substances

**Authors:** Kashi Brunetti, Giulia Serena Galletti, Elisabetta Catalani, Davide Cervia, Simona Del Quondam

PMC · DOI: 10.3390/toxics14010039 · Toxics · 2025-12-29

## TL;DR

This paper reviews how PFAS chemicals harm the gut by disrupting its structure, metabolism, and immune system, potentially leading to chronic inflammation and disease.

## Contribution

The paper integrates recent findings to highlight how PFAS affect intestinal health through multiple interconnected mechanisms.

## Key findings

- PFAS disrupt gut epithelial integrity by reducing tight-junction proteins and inducing oxidative stress.
- Metabolic changes and microbial imbalances caused by PFAS may lead to chronic intestinal inflammation.
- The review identifies key gaps in understanding PFAS toxicity and emphasizes the need for translational research.

## Abstract

Per- and Polyfluoroalkyl substances (PFAS) are highly persistent synthetic chemicals increasingly associated with adverse health outcomes. The gastrointestinal tract represents both a major route of exposure and a key target of PFAS toxicity. This review integrates updated evidence on how PFAS compromise intestinal homeostasis through interrelated structural, metabolic, and immunological mechanisms. PFAS disrupt epithelial integrity by down-regulating tight-junction proteins, inducing oxidative stress, and activating inflammasome signaling. Concurrently, metabolic reprogramming and PFAS-driven microbial dysbiosis contribute to barrier dysfunction and altered production of signal/metabolic molecules. These alterations may link environmental exposure to chronic intestinal inflammation and increase susceptibility to inflammatory bowel disease and related metabolic disorders. By synthesizing recent findings, key mechanistic gaps were highlighted also emphasizing the need for integrative experimental and translational studies to refine risk assessment in humans and develop preventive and therapeutic strategies.

## Linked entities

- **Diseases:** inflammatory bowel disease (MONDO:0005265)

## Full-text entities

- **Diseases:** Dysfunction (MESH:D006331), inflammation (MESH:D007249), metabolic disorders (MESH:D008659), Intestinal Toxicity (MESH:D007410), toxicity (MESH:D064420), inflammatory bowel disease (MESH:D015212)
- **Chemicals:** Per- and Polyfluoroalkyl Substances (MESH:D005466), PFAS (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12846221/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12846221/full.md

## References

129 references — full list in the complete paper: https://tomesphere.com/paper/PMC12846221/full.md

---
Source: https://tomesphere.com/paper/PMC12846221